Clinical observation of lobaplatin or cisplatin combined with pemetrexeddisodium in the treatment of advanced ade-nocarcinoma of lung

Le résumé fourni par la source

Objective To investigate the efficacy and toxicity of lobaplatin or cisplatin combined with pemetrexeddisodium for patients with advanced adenocarcinoma of lung. Methods Seventy-three patients with late stage lung adenocarcinoma were randomly divided into two groups. The 39 patients in LP regimen group recieved lobaplatin 30 mg/m2 ,iv,d1;pemetrexed disodium 500 mg/m2 ,iv,d1. Three weeks were a cycle. The 34 patients in CP regimen group recieved cisplatin 25 mg/m2 ,iv,d1-3;peme-trexed disodium 500 mg/m2 ,iv,d1,Three weeks were a cycle. The efficacy and toxicity were evaluated after at least two cycles of chemotherapy. Results The response rate（ RR）in LP regimen group was 56. 4%（22/39）,while that in CP regimen group was 58. 8%（20/34）,there was no significant difference between the two groups（P﹥0. 05）. Grade 3-4 thrombocytopenia rate in LP regimen group（17. 9%,7/39）was higher than that in CP regimen group（11. 8%,4/34）,but there was no significant difference be-tween the two groups（P﹥0. 05）. There was no difference in nephrotoxicity and neurotoxicity between the two groups（P﹥0. 05）. In LP regimen group,the incidence of grade 3 -4 gastrointestinal reaction was 0. 0%（0/39）,and was 14. 7%（5/34）in CP regimen group,there was significant difference between the two groups（ P﹤0. 05 ）. Conclusions Both LP and CP are safe and effective chemotherapy for patients with advanced lung adenocarcinoma. The effectiveness of lobaplatin with pemetrexeddisodium is similar to that of cisplatin with pemetrexeddisodium in initial treatment of advanced adenocarcinoma of lung,but lobaplatin causes less gastrointestinal reaction. Lobaplatin is well tolerant and has less toxicity. Key words: Lobaplatin Cisplatin Pemetrexed disodium Lung adenocarcinoma

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.